118 related articles for article (PubMed ID: 26055813)
1. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract][Full Text] [Related]
2. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract][Full Text] [Related]
3. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
Liu X; Chong Y; Tu Y; Liu N; Yue C; Qi Z; Liu H; Yao Y; Liu H; Gao S; Niu M; Yu R
J Hematol Oncol; 2016 Oct; 9(1):108. PubMed ID: 27733172
[TBL] [Abstract][Full Text] [Related]
4. CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.
Liu X; Chong Y; Liu H; Han Y; Niu M
Korean J Physiol Pharmacol; 2016 Mar; 20(2):161-8. PubMed ID: 26937212
[TBL] [Abstract][Full Text] [Related]
5. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
[TBL] [Abstract][Full Text] [Related]
6. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
7. The abnormal expression of chromosomal region maintenance 1 (CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells.
Zhang J; Xu X; Chen Y; Guan X; Zhu H; Qi Y
Bioengineered; 2022 Jan; 13(1):624-633. PubMed ID: 34898375
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer.
Wang Y; Wang Y; Xiang J; Ji F; Deng Y; Tang C; Yang S; Xi Q; Liu R; Di W
Cancer Lett; 2014 Feb; 343(1):6-13. PubMed ID: 24018641
[TBL] [Abstract][Full Text] [Related]
10. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.
van der Watt PJ; Maske CP; Hendricks DT; Parker MI; Denny L; Govender D; Birrer MJ; Leaner VD
Int J Cancer; 2009 Apr; 124(8):1829-40. PubMed ID: 19117056
[TBL] [Abstract][Full Text] [Related]
11. Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells.
Yan H; Tong J; Lin X; Han Q; Huang H
Mol Med Rep; 2015 Aug; 12(2):1783-8. PubMed ID: 25891642
[TBL] [Abstract][Full Text] [Related]
12. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
13. Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.
Liu X; Tu Y; Wang Y; Zhou D; Chong Y; Shi L; Liu G; Zhang X; Wu S; Li H; Gao S; Niu M; Yu R
Cancer Cell Int; 2020; 20():97. PubMed ID: 32256206
[TBL] [Abstract][Full Text] [Related]
14. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
15. Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway.
Shao WY; Yang YL; Yan H; Huang Q; Liu KJ; Zhang S
Cancer Biol Ther; 2017 Jan; 18(1):26-35. PubMed ID: 27981892
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway.
Shan Q; Li S; Cao Q; Yue C; Niu M; Chen X; Shi L; Li H; Gao S; Liang J; Yu R; Liu X
Korean J Physiol Pharmacol; 2020 May; 24(3):193-201. PubMed ID: 32392910
[TBL] [Abstract][Full Text] [Related]
17. Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway.
Kim JY; Yi BR; Go RE; Hwang KA; Nam KH; Choi KC
Environ Toxicol Pharmacol; 2014 May; 37(3):1264-74. PubMed ID: 24835555
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.
Zhang X; Liu J; Zang D; Wu S; Liu A; Zhu J; Wu G; Li J; Jiang L
Oncotarget; 2015 Jun; 6(17):15180-93. PubMed ID: 25893382
[TBL] [Abstract][Full Text] [Related]
19. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.
Noske A; Schwabe M; Weichert W; Darb-Esfahani S; Buckendahl AC; Sehouli J; Braicu EI; Budczies J; Dietel M; Denkert C
BMC Cancer; 2011 Jul; 11():294. PubMed ID: 21756326
[TBL] [Abstract][Full Text] [Related]
20. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.
Shen A; Wang Y; Zhao Y; Zou L; Sun L; Cheng C
Neurosurgery; 2009 Jul; 65(1):153-9; discussion 159-60. PubMed ID: 19574837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
